logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Infectious Disease and Immunisation

Results

Drugs

March 2020

Baloxavir marboxil for the post-exposure prevention of influenza in people aged 12 years and older

Baloxavir marboxil is given by mouth as tablets and works in a different way to existing flu medications by blocking a specific process which influenza viruses use to multiply within the body. There is evidence that this medication may be effective in people for whom existing flu medicines do not work. Additionally, only one dose of baloxavir marboxil is needed whereas existing flu prevention medications need to be taken over several days. If licenced, baloxavir marboxil may offer an additional prevention option for individuals who have been in contact with someone who has influenza.

Drugs

March 2020

Baloxavir marboxil for the treatment of influenza in patients aged 12 years and older and are at high risk of developing influenza complications

Baloxavir marboxil is given by mouth as tablets within 48 hours of symptom onset and works in a different way to existing flu medications by blocking a specific process which influenza viruses use to multiply within the body. There is evidence that this medication may be effective in people for whom existing flu medicines do not work. Additionally, only one dose of baloxavir marboxil is needed whereas existing flu medications need to be taken over several days. If licenced, baloxavir marboxil may offer an additional treatment option for patients with influenza.

Drugs

January 2020

Bulevirtide for chronic hepatitis delta virus infection

Bulevirtide is in clinical development for the treatment of chronic hepatitis Delta virus infection in adult patients with compensated liver disease. Hepatitis D is a viral infection of the liver that is dependent on the patient already being infected with hepatitis B virus. The co-infection is thought to be more severe and cause more damage to the liver than hepatitis B alone. Currently there are limited treatment options for the treatment of patients with chronic hepatitis D virus infection.

Drugs

November 2019

Cabotegravir (oral tablet) in combination with rilpivirine (oral tablet) for the short-term treatment of HIV-1 infection

Cabotegravir and rilpivirine tablets are in development as an oral lead-in therapy for a period of approximately one month as a short-term oral bridging treatment for Human Immunodeficiency Virus 1 (HIV-1) patients that are considered eligible for the long-acting injectable cabotegravir and rilpivirine therapy. HIV is a type of viral infection caused by a type of virus referred to as a retrovirus. HIV-1 is the most common and highly communicable type of HIV. HIV is a lifelong, chronic disease that nowadays can be managed with antiretroviral therapies (ARTs). Since HIV virus can quickly adapt and become resistant, a combination of ART drugs is normally used. Usually patients take between one and 4 or 6 tablets a day. Failing to do so will result in a weakened immune system and increased vulnerability to infections.

Drugs

November 2019

Fostemsavir for HIV-1 infection for heavily treatment-experienced adults

Fostemsavir is in clinical development for human immunodeficiency virus-1 (HIV-1) infection in heavily treatment-experienced adults. HIV is a virus that damages the cells in the immune system and weakens the body’s ability to fight everyday infections and diseases. HIV infection is incurable but there are effective treatments that enable most infected people to live a healthy life. Antiretroviral (ARV) medicines are used to treat HIV. However, poor adherence and the subsequent development of drug resistance is one reason why HIV treatment can fail. A drug-resistant HIV strain is one which is less susceptible to the effects of one or more anti-HIV drugs. For highly treatment-experienced patients who have failed on a number of treatment regimens and have limited treatment options, complex regimens including drugs to which the virus is partially resistant may be required.

Drugs

October 2019

Ibalizumab in combination with other antiretroviral(s) for multidrug-resistant HIV-1 infection

Ibalizumab in combination with other antiretroviral(s) has been developed for the treatment of adults infected with multidrug-resistant HIV-1 (MDR HIV-1). HIV is a virus that damages the cells in the immune system and weakens the ability to fight everyday infections and diseases. HIV-1 is the most common type of HIV infection, which is incurable but there are effective treatments that enable most infected people to live a healthy life. Antiretroviral medicines are used to treat HIV. There are however limited effective treatments for some treatment-experienced patients with extensive MDR HIV-1.

Drugs

October 2019

Cabotegravir in combination with rilpivirine long acting injection for the treatment of HIV-1 infection

Cabotegravir and rilpivirine long acting injections are in development for the treatment of HIV-1 patients that are considered clinically suitable for injectable therapy. HIV (Human Immunodeficiency Virus) is a type of viral infection caused by a virus referred as retrovirus. HIV-1 is the most common and highly communicable type of HIV. HIV is a lifelong, chronic disease that nowadays can be managed with antiretroviral therapies. Usually patients take between one and 4 or 6 tablets a day. Failing to do so will result in a weaken immune system and increased vulnerability to infections.

Drugs

August 2018

Baloxavir marboxil for treatment of influenza A or B infection in otherwise healthy patients aged 12 years and older

Baloxavir marboxil is the first new flu medication to be developed within the last 20 years. It works in a different way to existing flu medications by blocking a specific process which influenza viruses use to multiply within the body. There is evidence that this medication may be effective in people for whom existing flu medicines (oseltamivir) do not work. Additionally, only one dose of baloxavir marboxil is needed whereas existing flu medications need to be taken over several days. If licenced, baloxavir marboxil may offer an additional treatment option for patients with influenza A or B infection and for people who have suspected oseltamivir-resistant influenza.

Drugs

January 2018

RBX-2660 for the Treatment of Recurrent Clostridium Difficile Infection – third line

RBX-2660 is a therapy under development for recurrent CDI. It is a non-antibiotic therapy that consists of human-derived microorganisms (microbiota suspension). It is administered directly into the patient’s intestine through the rectum as an enema. RBX-2660 has the potential to treat patients re-infected by C. difficile that currently have limited treatment options available and are at risk of serious health consequences.

Drugs

March 2017

Cefiderocol for severe gram-negative infections

Cefiderocol is a new drug to treat severe infections, which are caused by a particular group of bacteria called gram-negative bacteria, which are increasingly resistant to many antibiotics. Infections such as pneumonia, complicated urinary tract infections and bloodstream infections, are serious infections and a huge problem for the NHS. They prolong patient stay in hospital …

Get Alerts